ED
CDNA icon

Exane Derivatives’s CareDx CDNA Stock Holding History

Exane Derivatives’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,888
Closed -$120K – 894
2021
Q3 		$120K Buy
1,888
+253
+15% +$19.3K 0.03% 501
2021
Q2 		$136K Sell
1,635
-769
-32% -$61.1K 0.03% 505
2021
Q1 		$164K Buy
+2,404
New +$187K 0.05% 329

Other funds holding CDNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Exane Derivatives's CDNA Position: Q4 2021 in Review

Exane Derivatives sold out of CareDx (CDNA) in Q4 2021, closing a stake of 1,888 shares — an estimated $120K sold.

Exane Derivatives first reported a position in CDNA in Q1 2021 and held it in 3 quarters. The position peaked at $164K in Q1 2021. 224 funds tracked by Wall St. Rank hold CDNA as of Q4 2021.

  • Exane Derivatives reported no remaining CareDx position as of Q4 2021 after selling out during the quarter.
  • Exane Derivatives sold 1,888 CareDx shares in Q4 2021, an estimated $120K.
  • Exane Derivatives first reported a position in CareDx in Q1 2021 and held it in 3 quarters.
  • Exane Derivatives's CareDx position peaked at $164K in Q1 2021.
  • 224 funds tracked by Wall St. Rank held CareDx as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.